13 Best Multibagger Stocks to Invest in Now
The global economic and geopolitical environment in 2025 is marked by uncertainty, trade tensions, and shifting monetary policies.
Capricor Therapeutics Inc. (CAPR)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | 1,360,200 | $13,506,786 | 2.59% | ||
| 2. | 700,000 | $6,951,000 | +75% | 1.34% | |
| 3. | 650,000 | $6,454,500 | 0.24% | ||
| 4. | 65,650 | $5,479,470 | 4.06% | ||
| 5. | 545,500 | $5,416,815 | +195% | 0.04% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $5.36 | 2,798,507 | $14,999,997.52 | 7,090,351 | 2024-09-20 | Filing | |
| $2.75 | 410 | $1,127.50 | 31,536 | 2023-10-12 | Filing | |
| $2.83 | 10,000 | $28,300.00 | 26,856 | 2023-10-10 | Filing | |
| $2.82 | 5,083 | $14,334.06 | 31,126 | 2023-10-09 | Filing | |
| $2.84 | 5,000 | $14,200.00 | 5,000 | 2023-10-06 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $64,258.00 | 14,772 | $949,219,176.00 | 0 | 2023-04-17 | Filing | |
| $4.06 | 3,000 | $12,180.00 | 0 | 2023-03-28 | Filing | |
| $3.77 | 28,215 | $106,370.55 | 12,747 | 2022-06-29 | Filing | |
| $4.44 | 17,775 | $78,921.00 | 40,962 | 2022-06-27 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 2,984,063 | $29,631,746 | 0% | |
| 2. | 2,305,078 | $22,889,425 | 0% | |
| 3. | 1,466,685 | $14,564,182 | 0% | |
| 4. | 1,385,900 | $13,761,987 | 0% | |
| 5. | 963,080 | $9,564,674 | 0% |
News See All
Capricor Therapeutics, Inc. (NASDAQ:CAPR) Q1 2025 Earnings Call Transcript
Capricor Therapeutics, Inc. (NASDAQ:CAPR) Q1 2025 Earnings Call Transcript May 13, 2025Capricor Therapeutics, Inc. misses on earnings expectations.
Capricor Therapeutics, Inc. (NASDAQ:CAPR) Q4 2024 Earnings Call Transcript
Operator: Good afternoon, ladies and gentlemen, and welcome to the Capricor Therapeutics Second (sic) [Fourth] Quarter 2024 Earnings Call. At this time, all participant lines are in listen-only mode.
10 Worst High-Risk High-Reward Growth Stocks To Buy
On March 14, Tom Lee managing partner and head of research at Fundstrat Global Advisors appeared on a CNBC interview to talk about how the markets react to crises and what approach investors should take...
Capricor Therapeutics, Inc. (CAPR): A Bull Case Theory
We came across a bullish thesis on Capricor Therapeutics, Inc. (CAPR) on wallstreetbets Subreddit Page by androidmj. In this article, we will summarize the bulls’ thesis on CAPR.
10 Best Small-Cap Growth Stocks to Buy Now
On November 4, 2024, Nick Sheridan, Portfolio Manager at Janus Henderson released a report on small-cap stocks exploring how these stocks offer unique growth and diversification opportunities.
Capricor Therapeutics, Inc. (NASDAQ:CAPR) Q3 2024 Earnings Call Transcript
Operator: Good afternoon, ladies and gentlemen and welcome to the Capricor's Third Quarter 2024 Financial Results and Corporate Update Call.
10 Best Multibagger Stocks To Buy Heading into 2025
November has been an eventful month so far for the market as the Fed cut rates by a quarter percentage and president-elect, Donald Trump won the election for the second time.
7 Best Russell 2000 Stocks to Buy According to Analysts
The investor sentiment remains bullish toward the market, especially since the Fed's recent decision to cut interest rates by half a percentage point, which is seen as a move to sustain economic health...
Capricor Therapeutics, Inc. (NASDAQ:CAPR) Q2 2024 Earnings Call Transcript
Operator: Good afternoon, ladies and gentlemen, and welcome to the Capricor Therapeutics Second Quarter 2024 Earnings Call. At this time, all participant lines are in a listen-only mode.